Mesoblast (MESO) FCF Payout Ratio Growth (3y) (2019 - 2023)
Mesoblast (MESO) FCF Payout Ratio Growth (3y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.12% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 2.70% |
| Dec 31, 2022 | 26.64% |
| Sep 30, 2022 | -39.18% |
| Jun 30, 2022 | 3.93% |
| Mar 31, 2022 | 54.96% |
| Dec 31, 2021 | -52.46% |
| Sep 30, 2021 | -31.20% |
| Jun 30, 2021 | 1.57% |
| Mar 31, 2021 | -74.59% |
| Dec 31, 2020 | -1.48% |
| Sep 30, 2020 | -7.48% |
| Jun 30, 2020 | -92.15% |
| Mar 31, 2020 | 40.60% |
| Dec 31, 2019 | -230.13% |
| Sep 30, 2019 | 8.50% |
| Jun 30, 2019 | -0.13% |
| Mar 31, 2019 | -30.83% |